Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Shares Outstanding (Diluted Average): 2021-2024

Historic Shares Outstanding (Diluted Average) for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $102.4 million.

  • ARS Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1.83% to $98.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.8 million, marking a year-over-year increase of 1.83%. This contributed to the annual value of $102.4 million for FY2024, which is 7.54% up from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Shares Outstanding (Diluted Average) is $102.4 million, which was up 7.54% from $95.2 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Shares Outstanding (Diluted Average) registered a high of $102.4 million during FY2024, and its lowest value of $28.9 million during FY2021.
  • Over the past 3 years, ARS Pharmaceuticals' median Shares Outstanding (Diluted Average) value was $95.2 million (recorded in 2023), while the average stood at $79.2 million.
  • Data for ARS Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 138.30% (in 2023) over the last 5 years.
  • Over the past 4 years, ARS Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $28.9 million in 2021, then surged by 38.39% to $40.0 million in 2022, then surged by 138.30% to $95.2 million in 2023, then grew by 7.54% to $102.4 million in 2024.